YD Bio Ltd
YDES, YDESW · Services-Medical Laboratories · EDGAR filings ↗
Grade
D44Taiwan/US clinical-stage diagnostics and exosome biotech with explicit going-concern doubt and pre-revenue pipelines.
Strengths
- Revenue grew 17% (61st pct) with a 5.9 current ratio
- Active LDT cancer-testing revenue across 44 states provides some commercial base
Risks
- Substantial doubt about going concern and only ~3 quarters of cash runway (7.7th pct)
- Deeply negative operating/net margins (-883%/-1393%); ROE is a negative-equity artifact
- Binary, capital-dependent clinical and acquisition roadmap with FDA approvals years away
Notable findings
- Going concern● Substantial doubt exists regarding our ability to continue as a going concern, and YD Bio may need additional financing to implement its business plan
- Net lossNet loss (net margin -1392.6%)
- Cash burnNegative free cash flow (-8.0M)
Key metrics
Return on equity
291.0%
Return on assets
-60.3%
Current ratio
5.9×
Free cash flow
-$8M
Tangible book value
-$5M
Cash & investments
$6M
Cash runway
3q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-31 | Lu Shao-Ta | Option exercise | 2.1K | — |
| 2026-03-31 | Chang Kochi | Option exercise | 2.1K | — |
All non-derivative Form 4 activity (SEC), newest first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-04-30 | 2025-12-31 | 0001213900-26-050282 ↗ |